Bone sarcomas: From biology to targeted therapies

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Gaspar, Nathalie ^a   Di Giannatale, Angela ^a   Geoerger, Birgit ^a   Redini, Françoise ^b   Corradini, Nadège ^c   Enz Werle, Natacha ^d   Tirode, Franck ^e   Marec Berard, Perrine ^f   Gentet, Jean Claude ^g   Laurence, Valérie ^h   Piperno Neumann, Sophie ^h   Oberlin, Odile ^a   Brugieres, Laurence ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e INSERM   (France)

^f CENTRE LÉON BÉRARD   (France)

^g TIMONE HOSPITAL   (France)

^h INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ALISERTIB; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AURORA A INHIBITOR; CIXUTUMUMAB; COMPLEMENTARY RNA; DALOTUZUMAB; DASATINIB; DINACICLIB; EVEROLIMUS; IFOSFAMIDE; IMATINIB; IRINOTECAN; MITHRAMYCIN; NUTLIN 3; PAZOPANIB; R 1507; RAPAMYCIN; REXIN G; RIDAFOROLIMUS; ROBATUMUMAB; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YK 4279; ZOLEDRONIC ACID;

BIOLOGY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EWING SARCOMA; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84871658126     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/301975     Document Type: Review

References (188)

1. Ladenstein R., Pötschger U., Le Deley M. C., Whelan J., Paulussen M., Oberlin O., Van Den Berg H., Dirksen U., Hjorth L., Michon J., Lewis I., Craft A., Jürgens H., Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. Journal of Clinical Oncology 2010 28 20 3284 3291 2-s2.0-77954727583 10.1200/JCO.2009.22.9864
2. Oberlin O., Deley M. C. L., Bui B. N. G., Gentet J. C., Philip T., Terrier P., Carrie C., Mechinaud F., Schmitt C., Babin-Boillettot A., Michon J., Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the french society of paediatric oncology (EW88 study). British Journal of Cancer 2001 85 11 1646 1654 2-s2.0-0035977183 10.1054/bjoc.2001.2150
3. Le Deley M. C., Guinebretière J. M., Gentet J. C., Pacquement H., Pichon F., Marec-Bérard P., Entz-Werlé N., Schmitt C., Brugières L., Vanel D., Dupoüy N., Tabone M. D., Kalifa C., SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. European Journal of Cancer 2007 43 4 752 761 2-s2.0-33947710840 10.1016/j.ejca.2006.10.023
4. Pakos E. E., Nearchou A. D., Grimer R. J., Prognostic factors and outcomes for osteosarcoma: an international collaboration. European Journal of Cancer 2009 45 13 2367 2375
5. Stahl M., Ranft A., Paulussen M., Bölling T., Vieth V., Bielack S., Görtitz I., Braun-Munzinger G., Hardes J., Jürgens H., Dirksen U., Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatric Blood and Cancer 2011 57 4 549 553 2-s2.0-79961201233 10.1002/pbc.23040
6. Tirode F., Laud-Duval K., Prieur A., Delorme B., Charbord P., Delattre O., Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007 11 5 421 429 2-s2.0-34247570879 10.1016/j.ccr.2007.02.027
7. Benini S., Manara M. C., Cerisano V., Perdichizzi S., Strammiello R., Serra M., Picci P., Scotlandi K., Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. International Journal of Cancer 2004 108 3 358 366 2-s2.0-0347626094 10.1002/ijc.11576
8. Erkizan H. V., Uversky V. N., Toretsky J. A., Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clinical Cancer Research 2010 16 16 4077 4083 2-s2.0-77955729370 10.1158/1078-0432.CCR- 09-2261
9. Tanaka K., Iwakuma T., Harimaya K., Sato H., Iwamoto Y., EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. Journal of Clinical Investigation 1997 99 2 239 247 2-s2.0-0031025207
10. Maksimenko A., Lambert G., Bertrand J. R., Fattal E., Couvreur P., Malvy C., Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides. Annals of the New York Academy of Sciences 2003 1002 72 77 2-s2.0-1342268523 10.1196/annals.1281.017
11. Hu-Lieskovan S., Heidel J. D., Bartlett D. W., Davis M. E., Triche T. J., Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Research 2005 65 19 8984 8992 2-s2.0-25444482607 10.1158/0008-5472.CAN-05-0565
12. Grohar P. J., Woldemichael G. M., Griffin L. B., Mendoza A., Chen Q. R., Yeung C., Currier D. G., Davis S., Khanna C., Khan J., McMahon J. B., Helman L. J., Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. Journal of the National Cancer Institute 2011 103 12 962 978 2-s2.0-79959714071 10.1093/jnci/djr156
13. Erkizan H. V., Kong Y., Merchant M., Schlottmann S., Barber-Rotenberg J. S., Yuan L., Abaan O. D., Chou T. H., Dakshanamurthy S., Brown M. L., Ren A., Toretsky J. A., A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nature Medicine 2009 15 7 750 756 2-s2.0-67650447477 10.1038/nm.1983
14. Baruchel S., Pappo A., Krailo M., A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. European Journal of Cancer 2012 48 4 579 585
15. Grohar P. J., Griffin L. B., Yeung C., Chen Q. R., Pommier Y., Khanna C., Khan J., Helman L. J., Ecteinascidin 743 interferes with the activity of EWS-FLI1 in ewing sarcoma cells. Neoplasia 2011 13 2 145 153 2-s2.0-79951471957 10.1593/neo.101202
16. Lau L., Supko J. G., Blaney S., Hershon L., Seibel N., Krailo M., Qu W., Malkin D., Jimeno J., Bernstein M., Baruchel S., A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clinical Cancer Research 2005 11 2 I 672 677 2-s2.0-19944426087
17. Delaloge S., Yovine A., Taamma A., Riofrio M., Brain E., Raymond E., Cottu P., Goldwasser F., Jimeno J., Misset J. L., Marty M., Cvitkovic E., Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. Journal of Clinical Oncology 2001 19 5 1248 1255 2-s2.0-0035281734
18. Le Cesne A., Yovine A., Blay J. Y., Delaloge S., Maki R. G., Misset J. L., Frontelo P., Nieto A., Jiao J. J., Demetri G. D., A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Investigational New Drugs 2012 30 1193 1202 2-s2.0-79953747432 10.1007/s10637-011-9662-0
19. Mateo-Lozano S., Gokhale P. C., Soldatenkov V. A., Dritschilo A., Tirado O. M., Notario V., Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clinical Cancer Research 2006 12 22 6781 6790 2-s2.0-33845322974 10.1158/1078-0432.CCR-06-0609
20. Tap W. D., AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): phase II results. Journal of Clinical Oncology 2010 28, supplement, abstract 10001 15s
21. Olmos D., Postel-Vinay S., Molife L. R., Okuno S. H., Schuetze S. M., Paccagnella M. L., Batzel G. N., Yin D., Pritchard-Jones K., Judson I., Worden F. P., Gualberto A., Scurr M., de Bono J. S., Haluska P., Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. The Lancet Oncology 2010 11 2 129 135 2-s2.0-75249097799 10.1016/S1470-2045(09)70354-7
22. Pappo A. S., Patel S. R., Crowley J., R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. Journal of Clinical Oncology 2010 29 34 4541 4547
23. Juergens H., Daw N. C., Geoerger B., Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. Journal of Clinical Oncology 2011 29 34 4534 4540
24. Malempati S., Weigel B., Ingle A. M., Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. Journal of Clinical Oncology 2012 30 3 256 262
25. Anderson P., Skubitz K., Miller R., Activity of SCH 717454 in subjects with relapsed osteosarcoma or Ewing's sarcoma (study P04720). Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society 2007 London, UK Abstract #35094
26. Ho A. L., Schwartz G. K., Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? Journal of Clinical Oncology 2011 29 34 4581 4583
27. Scotlandi K., Manara M. C., Serra M., Marino M. T., Ventura S., Garofalo C., Alberghini M., Magagnoli G., Ferrari S., Lopez-Guerrero J. A., Llombard-Bosch A., Picci P., Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. European Journal of Cancer 2011 47 8 1258 1266 2-s2.0-79955541612 10.1016/j.ejca.2011.01. 007
28. Garofalo C., Manara M. C., Nicoletti G., Marino M. T., Lollini P. L., Astolfi A., Pandini G., López-Guerrero J. A., Schaefer K. L., Belfiore A., Picci P., Scotlandi K., Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011 30 24 2730 2740 2-s2.0-79958863370 10.1038/onc.2010.640
29. Gazitt Y., Kolaparthi V., Moncada K., Thomas C., Freeman J., Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. International Journal of Oncology 2009 34 2 551 561 2-s2.0-64549109015 10.3892/ijo-00000181
30. Wan X., Mendoza A., Khanna C., Helman L. J., Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Research 2005 65 6 2406 2411 2-s2.0-16844366544 10.1158/0008-5472.CAN-04-3135
31. Mora J., Rodríguez E., de Torres C., Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. Pediatric Blood & Cancer 2012 58 4 532 538
32. Fouladi M., Laningham F., Wu J., O'Shaughnessy M. A., Molina K., Broniscer A., Spunt S. L., Luckett I., Stewart C. F., Houghton P. J., Gilbertson R. J., Furman W. L., Phase I study of everolimus in pediatric patients with refractory solid tumors. Journal of Clinical Oncology 2007 25 30 4806 4812 2-s2.0-36049023679 10.1200/JCO.2007.11.4017
33. Spunt S. L., Grupp S. A., Vik T. A., Santana V. M., Greenblatt D. J., Clancy J., Berkenblit A., Krygowski M., Ananthakrishnan R., Boni J. P., Gilbertson R. J., Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. Journal of Clinical Oncology 2011 29 21 2933 2940 2-s2.0-79960744694 10.1200/JCO.2010.33.4649
34. Chawla S. P., Staddon A. P., Baker L. H., Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. Journal of Clinical Oncology 2012 30 1 78 84
35. Chawla S. P., Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Journal of Clinical Oncology 2011 29, supplement, abstract 10005
36. Naing A., LoRusso P., Fu S., Insulin Growth Factor-Receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clinical Cancer Research 2012 18 9 2625 2631
37. Kubo T., Piperdi S., Rosenblum J., Antonescu C. R., Chen W., Kim H. S., Huvos A. G., Sowers R., Meyers P. A., Healey J. H., Gorlick R., Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008 112 10 2119 2129 2-s2.0-43049095679 10.1002/cncr.23437
38. Merchant M. S., Woo C. W., Mackall C. L., Thiele C. J., Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. Journal of the National Cancer Institute 2002 94 22 1673 1679 2-s2.0-0037146220
39. Hotfilder M., Lanvers C., Jürgens H., Boos J., Vormoor J., C-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemotherapy and Pharmacology 2002 50 2 167 169 2-s2.0-0036352770 10.1007/s00280-002-0477-8
40. Chugh R., Wathen J. K., Maki R. G., Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. Journal of Clinical Oncology 2009 27 19 3148 3153
41. Chao J., Budd G. T., Chu P., Frankel P., Garcia D., Junqueira M., Loera S., Somlo G., Sato J., Chow W. A., Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFR α-expressing ewing sarcoma family of tumors and desmoplastic small round cell tumors. AntiCancer Research 2010 30 2 547 552 2-s2.0-77950547753
42. Bond M., Bernstein M. L., Pappo A., Schultz K. R., Krailo M., Blaney S. M., Adamson P. C., A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a children's oncology group study. Pediatric Blood and Cancer 2008 50 2 254 258 2-s2.0-37549041711 10.1002/pbc.21132
43. González I., Andreu E. J., Panizo A., Inogés S., Fontalba A., Fernández-Luna J. L., Gaboli M., Sierrasesúmaga L., Martín-Algarra S., Pardo J., Prósper F., De Alava E., Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clinical Cancer Research 2004 10 2 751 761 2-s2.0-10744222923 10.1158/1078-0432.CCR-0778-03
44. Timeus F., Crescenzio N., Fandi A., Doria A., Foglia L., di Montezemolo L. C., In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncology Reports 2008 19 2 353 359 2-s2.0-38749092531
45. Hingorani P., Zhang W., Gorlick R., Kolb E. A., Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clinical Cancer Research 2009 15 10 3416 3422 2-s2.0-66149192409 10.1158/1078-0432.CCR-08-1657
46. Aplenc R., Blaney S. M., Strauss L. C., Balis F. M., Shusterman S., Ingle A. M., Agrawal S., Sun J., Wright J. J., Adamson P. C., Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. Journal of Clinical Oncology 2011 29 7 839 844 2-s2.0-79952319155 10.1200/JCO.2010.30.7231
47. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., Bottos A., Gammaitoni L., Migliardi G., Camussi G., Alberghini M., Torchio B., Ferrari S., Bussolino F., Fagioli F., Picci P., Aglietta M., Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Molecular Cancer 2009 8, article 118 2-s2.0-74549210540 10.1186/1476-4598-8-118
48. Grignani G., Palmerini E., Dileo P., A phase II trial of sorafenib in relapsed and unresectable high-grade 10 osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Annals of Oncology 2012 23 2 508 516
49. Maris J. M., Courtright J., Houghton P. J., Morton C. L., Kolb E. A., Lock R., Tajbakhsh M., Reynolds C. P., Keir S. T., Wu J., Smith M. A., Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric Blood and Cancer 2008 51 1 42 48 2-s2.0-44149115014 10.1002/pbc.21535
50. DuBois S. G., Shusterman S., Reid J. M., Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol 2012 69 4 1021 1027
51. DuBois S. G., Shusterman S., Ingle A. M., Ahern C. H., Reid J. M., Wu B., Baruchel S., Glade-Bender J., Ivy P., Grier H. E., Adamson P. C., Blaney S. M., Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clinical Cancer Research 2011 17 15 5113 5122 2-s2.0-79960983264 10.1158/1078-0432.CCR-11-0237
52. Keir S. T., Maris J. M., Lock R., Kolb E. A., Gorlick R., Carol H., Morton C. L., Reynolds C. P., Kang M. H., Watkins A., Houghton P. J., Smith M. A., Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood and Cancer 2010 55 6 1126 1133 2-s2.0-77958598570 10.1002/pbc.22712
53. Kumar S., Mokhtari R. B., Sheikh R., Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clinical Cancer Research 2011 17 17 5656 5667
54. Glade Bender J. L., Lee A., Adamson P. C., Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): a Children's Oncology Group Phase I Consortium Trial. Journal of Clinical Oncology 2011 29, supplement, abstract 9501
55. Bachelot T., Bourgier C., Cropet C., Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of Clinical Oncology 2012 30 22 2718 2724
56. Rugo H. S., Keck S., Reversing hormone resistance: have we found the golden key? Journal of Clinical Oncology 2012 30 22 2707 2709
57. Fu W., Le M., Chu B., Wang X., Bui M. M., Gemmer J., Altiok S., Pledger W. J., The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Molecular Cancer Therapeutics 2011 10 6 1018 1027 2-s2.0-79958716819 10.1158/1535-7163.MCT-11-0167
58. Chawla S. P., Chua V. S., Fernandez L., Quon D., Saralou A., Blackwelder W. C., Hall F. L., Gordon E. M., Phase I/II and phase II studies of targeted gene delivery In vivo: intravenous rexin-g for chemotherapy-resistant sarcoma and osteosarcoma. Molecular Therapy 2009 17 9 1651 1657 2-s2.0-69949145988 10.1038/mt.2009.126
59. Maris J. M., Morton C. L., Gorlick R., Kolb E. A., Lock R., Carol H., Keir S. T., Reynolds C. P., Kang M. H., Wu J., Smith M. A., Houghton P. J., Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer 2010 55 1 26 34 2-s2.0-77952703733 10.1002/pbc.22430
60. Morales A. G., Brassesco M. S., Pezuk J. A., Oliveira J. C., Montaldi A. P., Sakamoto-Hojo E. T., Scrideli C. A., Tone L. G., BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anti-Cancer Drugs 2011 22 995 1001 2-s2.0-79961112803 10.1097/CAD.0b013e32834a16d4
61. Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E. A., In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science 2004 303 5659 844 848 2-s2.0-10744221485 10.1126/science.1092472
62. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B. T., Qing W., Packman K., Myklebost O., Heimbrook D. C., Vassilev L. T., Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proceedings of the National Academy of Sciences of the United States of America 2006 103 6 1888 1893 2-s2.0-32444449180 10.1073/pnas.0507493103
63. Sonnemann J., Palani C. D., Wittig S., Becker S., Eichhorn F., Voigt A., Beck J. F., Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. European Journal of Cancer 2011 47 9 1432 1441 2-s2.0-79957545097 10.1016/j.ejca.2011.01.015
64. Javelaud D., Besançon F., NF- B activation results in rapid inactivation of JNK in TNF α-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF- B. Oncogene 2001 20 32 4365 4372 2-s2.0-0035913158 10.1038/sj.onc.1204570
65. Palani C. D., Beck J. F., Sonnemann J., Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Investigational New Drugs 2010 1 12 2-s2.0-77955027218 10.1007/s10637-010-9510-7
66. Bruheim S., Xi Y., Ju J., Fodstad O., Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clinical Cancer Research 2009 15 23 7161 7169 2-s2.0-73149111923 10.1158/1078-0432.CCR-08-2816
67. Puglisi M., van Doorn L., Blanco-Codesido M., A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors. Journal of Clinical Oncology 2011 29, supplement, abstract 2518
68. Picarda G., Lamoureux F., Geffroy L., Delepine P., Montier T., Laud K., Tirode F., Delattre O., Heymann D., Rédini F., Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clinical Cancer Research 2010 16 8 2363 2374 2-s2.0-77950980364 10.1158/1078-0432.CCR-09-1779
69. Wang Y., Mandal D., Wang S., Kleinerman E. S., Pollock R. E., Lev D., Hayes-Jordan A., Platelet-derived growth factor receptor β inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer 2010 116 16 3892 3902 2-s2.0-77956792568 10.1002/cncr.25107
70. Kaplan-Lefko P. J., Graves J. D., Zoog S. J., Pan Y., Wall J., Branstetter D. G., Moriguchi J., Coxon A., Huard J. N., Xu R., Peach M. L., Juan G., Kaufman S., Chen Q., Bianchi A., Kordich J. J., Ma M., Foltz I. N., Gliniak B. C., Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biology and Therapy 2010 9 8 618 631 2-s2.0-77952912435
71. Chawla S. P., Lockhart A. C., Azad N., Efficacy and safety of conatumumab plus AMG 479 in patients with advanced sarcoma. Proceedings of the CTOS Meeting 2010 Chicago, Ill, USA
72. Demetri G. D., Le Cesne A., Chawla S. P., First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. European Journal of Cancer 2012 48 4 547 563
73. Houghton P. J., Kang M. H., Reynolds C. P., Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr Blood Cancer 2012 58 4 636 639
74. Holt S. V., Brookes K. E., Dive C., Makin G. W. J., Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncology Reports 2011 25 4 1177 1181 2-s2.0-79952230990 10.3892/or.2011.1167
75. Brenner J. C., Feng F. Y., Han S., PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Research 2012 72 7 1608 1613
76. Wu Y. F., Liang X. J., Liu Y. Y., Gong W., Liu J. X., Wang X. P., Zhuang Z. Q., Guo Y., Shen H. Y., +Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma 2010 57 6 501 506 2-s2.0-79952109502
77. Zou J., Gan M., Mao N., Zhu X., Shi Q., Yang H., Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin. Archives of Medical Research 2010 41 3 162 169 2-s2.0-77953527629 10.1016/j.arcmed.2010.04.006
78. Huang J., Liu K., Yu Y., Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 2012 8 2 275 277
79. Huang J., Ni J., Liu K., HMGB1 promotes drug resistance in osteosarcoma. Cancer Research 2012 72 1 230 238
80. Rao N. V., Argyle B., Xu X., Reynolds P. R., Walenga J. M., Prechel M., Prestwich G. D., MacArthur R. B., Walters B. B., Hoidal J. R., Kennedy T. P., Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. American Journal of Physiology 2010 299 1 C97 C110 2-s2.0-77953772222 10.1152/ajpcell.00009.2010
81. Sotillo-Piñeiro E., Sierrasesúmaga L., Patiño- García A., Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatric Research 2004 55 2 231 235 2-s2.0-1642555901 10.1203/01.PDR.0000102455.36737.3C
82. Fujimori J., Matsuo T., Shimose S., Kubo T., Ishikawa M., Yasunaga Y., Ochi M., Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. Journal of Orthopaedic Research 2011 29 1707 1711 2-s2.0-79955888726 10.1002/jor.21451
83. Takahashi A., Higashino F., Aoyagi M., Yoshida K., Itoh M., Kyo S., Ohno T., Taira T., Ariga H., Nakajima K., Hatta M., Kobayashi M., Sano H., Kohgo T., Shindoh M., EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Research 2003 63 23 8338 8344 2-s2.0-10744231438
84. Trieb K., Blahovec H., Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro. International Journal of Biochemistry and Cell Biology 2003 35 7 1066 1070 2-s2.0-0037411184 10.1016/S1357-2725(02)00308-4
85. Uziel O., Fenig E., Nordenberg J., Beery E., Reshef H., Sandbank J., Birenbaum M., Bakhanashvili M., Yerushalmi R., Luria D., Lahav M., Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. British Journal of Cancer 2005 92 10 1881 1891 2-s2.0-20344374146 10.1038/sj.bjc.6602592
86. Lanvers-Kaminsky C., Winter B., Koling S., Frodermann B., Braun Y., Schaefer K. L., Diallo R., Koenemann S., Wai D., Willich N., Poremba C., Schuck A., Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo. Oncology Reports 2005 14 3 751 758 2-s2.0-24644477096
87. Schuck A., Poremba C., Lanvers C., Könemann S., Schleifer T., Wai D., Horn K., Hesselmann S., Braun Y., Frodermann B., Schäfer K. L., Diallo R. I., Rübe C. E., Rübe C., Dockhorn-Dworniczaks B., Willich N., Radiation-induced changes of telomerase activity in a human Ewing xenograft tumor. Strahlentherapie und Onkologie 2002 178 12 701 708 2-s2.0-18744374444 10.1007/s00066-002-0992-x
88. Stewart K. S., Kleinerman E. S., Tumor vessel development and expansion in Ewing's sarcoma: a review of the vasculogenesis process and clinical trials with vascular-targeting agents. Sarcoma 2011 2011 7 10.1155/2011/165837 165837
89. Mizobuchi H., García-Castellano J. M., Philip S., Healey J. H., Gorlick R., Hypoxia markers in human osteosarcoma: an exploratory study. Clinical Orthopaedics and Related Research 2008 466 9 2052 2059 2-s2.0-50649118599 10.1007/s11999-008-0328-y
90. Bajpai J., Sharma M., Sreenivas V., Kumar R., Gamnagatti S., Khan S. A., Rastogi S., Malhotra A., Bakhshi S., VEGF expression as a prognostic marker in osteosarcoma. Pediatric Blood and Cancer 2009 53 6 1035 1039 2-s2.0-71049161801 10.1002/pbc.22178
91. Yang Q. C., Zeng B. F., Shi Z. M., Dong Y., Jiang Z. M., Huang J., Lv Y. M., Yang C. X., Liu Y. W., Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. Journal of Experimental and Clinical Cancer Research 2006 25 4 593 599 2-s2.0-33846625170
92. Aryee D. N. T., Niedan S., Kauer M., Schwentner R., Bennani-Baiti I. M., Ban J., Muehlbacher K., Kreppel M., Walker R. L., Meltzer P., Poremba C., Kofler R., Kovar H., Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's Sarcoma cells In vitro. Cancer Research 2010 70 10 4015 4023 2-s2.0-77952801325 10.1158/0008-5472.CAN-09-4333
93. Yang Q. C., Zeng B. F., Dong Y., Shi Z. M., Jiang Z. M., Huang J., Overexpression of hypoxia-inducible factor-1 αin human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Japanese Journal of Clinical Oncology 2007 37 2 127 134 2-s2.0-34447635558 10.1093/jjco/hyl137
94. Knowles H. J., Schaefer K. L., Dirksen U., Athanasou N. A., Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor. BMC Cancer 2010 10, article 372 2-s2.0-77954560445 10.1186/1471-2407-10-372
95. Maris J. M., Courtright J., Houghton P. J., Morton C. L., Gorlick R., Kolb E. A., Lock R., Tajbakhsh M., Reynolds C. P., Keir S. T., Wu J., Smith M. A., Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer 2008 50 3 581 587 2-s2.0-38549164180 10.1002/pbc.21232
96. Morton C. L., Maris J. M., Keir S. T., Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatric Blood & Cancer 2012 58 4 566 571
97. Pencreach E., Guérin E., Nicolet C., Lelong-Rebel I., Voegeli A. C., Oudet P., Larsen A. K., Gaub M. P., Guenot D., Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-lnducible factor-1 αaxis. Clinical Cancer Research 2009 15 4 1297 1307 2-s2.0-63149114714 10.1158/1078-0432.CCR-08-0889
98. PosthumaDeBoer J., Witlox M. A., Kaspers G. J., van Royen B. J., Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clinical and Experimental Metastasis 2011 28 5 493 503
99. Hughes D. P. M., How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treatment and Research 2009 152 479 496 2-s2.0-77953674754 10.1007/978-1-4419-0284-9-28
100. Baliko F., Bright T., Poon R., Cohen B., Egan S. E., Alman B. A., Inhibition of notch signaling induces neural differentiation in Ewing sarcoma. American Journal of Pathology 2007 170 5 1686 1694 2-s2.0-34250796873 10.2353/ajpath.2007.060971
101. Deangelo D. J., Stone R. M., Silverman L. B., A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. Journal of Clinical Oncology 24, 8S, abstract 6585 ASCO Annual Meeting Proceedings Part I, 2006
102. Fouladi M., Stewart C. F., Olson J., Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Clinical Oncology 2011 29 26 3529 3534
103. Coltella N., Manara M. C., Cerisano V., Trusolino L., Di Renzo M. F., Scotlandi K., Ferracini R., Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. The FASEB Journal 2003 17 9 1162 1164 2-s2.0-0038380439
104. Entz-Werle N., Lavaux T., Metzger N., Stoetzel C., Lasthaus C., Marec P., Kalifa C., Brugieres L., Pacquement H., Schmitt C., Tabone M. D., Gentet J. C., Lutz P., Babin A., Oudet P., Gaub M. P., Perrin-Schmitt F., Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia 2007 9 8 678 688 2-s2.0-34548259435 10.1593/neo.07367
105. Liao A. T., McCleese J., Kamerling S., Christensen J., London C. A., A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Veterinary and Comparative Oncology 2007 5 3 177 196 2-s2.0-64849093206 10.1111/j.1476-5829.2007.00137.x
106. Sampson E. R., Martin B. A., Morris A. E., Xie C., Schwarz E. M., O'Keefe R. J., Rosier R. N., The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. Journal of Bone and Mineral Research 2011 26 6 1283 1294 2-s2.0-79958803354 10.1002/jbmr.336
107. Cai Y., Mohseny A. B., Karperien M., Hogendoorn P. C. W., Zhou G., Cleton-Jansen A. M., Inactive Wnt/ β -catenin pathway in conventional high-grade osteosarcoma. Journal of Pathology 2010 220 1 24 33 2-s2.0-73649132981 10.1002/path.2628
108. Brail L. H., Gray J. E., Burris H., A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin. Journal of Clinical Oncology 2011 29, 15s, supplement, abstract 3030
109. Worth L. L., Lafleur E. A., Jia S. F., Kleinerman E. S., Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncology Reports 2002 9 4 823 827 2-s2.0-0036636786
110. Krishnan K., Khanna C., Helman L. J., The biology of metastases in pediatric sarcomas. Cancer Journal 2005 11 4 306 313 2-s2.0-32944470425
111. Wan X., Kim S. Y., Guenther L. M., Mendoza A., Briggs J., Yeung C., Currier D., Zhang H., MacKall C., Li W. J., Tuan R. S., Deyrup A. T., Khanna C., Helman L., Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 2009 28 38 3401 3411 2-s2.0-70349440966 10.1038/onc.2009.206
112. Tsagaraki I., Tsilibary E. C., Tzinia A. K., TIMP-1 interaction with αv β 3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF- α-induced apoptosis. Cell and Tissue Research 2010 342 1 87 96 2-s2.0-77957706779 10.1007/s00441-010-1025-1
113. MacDonald T. J., Stewart C. F., Kocak M., Goldman S., Ellenbogen R. G., Phillips P., Lafond D., Poussaint T. Y., Kieran M. W., Boyett J. M., Kun L. E., Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. Journal of Clinical Oncology 2008 26 6 919 924 2-s2.0-39749191543 10.1200/JCO.2007.14.1812
114. De Angulo G., Hernandez M., Morales-Arias J., Herzog C. E., Anderson P., Wolff J., Kleinerman E. S., Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. Journal of Pediatric Hematology/Oncology 2007 29 1 48 52 2-s2.0-33846445664 10.1097/MPH.0b013e31802d3e3e
115. Moore C., Eslin D., Levy A., Roberson J., Giusti V., Sutphin R., Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatric Blood and Cancer 2010 55 6 1096 1102 2-s2.0-77954695842 10.1002/pbc.22673
116. Sancéau J., Poupon M. F., Delattre O., Sastre-Garau X., Wietzerbin J., Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002 21 50 7700 7709 2-s2.0-0037206936 10.1038/sj.onc.1205881
117. Sancéau J., Wietzerbin J., Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon- αor interferon- β with ifosfamide. Annals of the New York Academy of Sciences 2004 1030 170 178 2-s2.0-15044342949 10.1196/annals.1329.022
118. Berghuis D., Santos S. J., Baelde H. J., Taminiau A. H. M., Maarten Egeler R., Schilham M. W., Hogendoorn P. C. W., Lankester A. C., Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression. Journal of Pathology 2011 223 3 347 357 2-s2.0-78650618910 10.1002/path.2819
119. Fujiwara T., Fukushi J., Yamamoto S., Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. American Journal of Pathology 2011 179 3 1157 1170
120. Gaspar N., Rey A., Bérard P. M., Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study. European Journal of Cancer 2012 48 9 1376 1385
121. Liu B., Shi Z. L., Feng J., Tao H. M., Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biology International 2008 32 5 494 501 2-s2.0-43849106469 10.1016/j.cellbi.2007.10.008
122. Gendy A. S., Lipskar A., Glick R. D., Steinberg B. M., Edelman M., Soffer S. Z., Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. Journal of Pediatric Surgery 2011 46 1 108 114 2-s2.0-78751527395 10.1016/j.jpedsurg.2010.09.074
123. Lipinski M., Braham K., Philip I., Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Research 1987 47 1 183 187 2-s2.0-0023107214
124. Heiner J. P., Miraldi F., Kallick S., Makley J., Neely J., Smith-Mensah W. H., Cheung N. K. V., Localization of G(D2)-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Research 1987 47 20 5377 5381 2-s2.0-0023525967
125. Yu A. L., Gilman A. L., Ozkaynak M. F., Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. New England Journal of Medicine 2010 363 14 1324 1334
126. Yu A. L., Uttenreuther-Fischer M. M., Huang C. S., Tsui C. C., Gillies S. D., Reisfeld R. A., Kung F. H., Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. Journal of Clinical Oncology 1998 16 6 2169 2180 2-s2.0-0031750167
127. Kailayangiri S., Altvater B., Meltzer J., The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. British Journal of Cancer 2012 106 6 1123 1133
128. Waller E. K., The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 2007 12 2 22 26 2-s2.0-38449111918 10.1634/theoncologist.12-S2-22
129. Arndt C. A. S., Koshkina N. V., Inwards C. Y., Hawkins D. S., Krailo M. D., Villaluna D., Anderson P. M., Goorin A. M., Blakely M. L., Bernstein M., Bell S. A., Ray K., Grendahl D. C., Marina N., Kleinerman E. S., Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group. Clinical Cancer Research 2010 16 15 4024 4030 2-s2.0-77955122716 10.1158/1078-0432.CCR-10-0662
130. Meyer-Wentrup F., Richter G., Burdach S., Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope. Pediatric Hematology and Oncology 2005 22 4 297 308 2-s2.0-20044362414 10.1080/08880010590935194
131. Kubo T., Shimose S., Matsuo T., Fujimori J., Arihiro K., Ochi M., Interferon- α/ β receptor as a prognostic marker in osteosarcoma. Journal of Bone and Joint Surgery Series A 2011 93 6 519 526 2-s2.0-79952756697 10.2106/JBJS.J.00198
132. Buddingh E. P., Kuijjer M. L., Duim R. A. J., Bürger H., Agelopoulos K., Myklebost O., Serra M., Mertens F., Hogendoorn P. C. W., Lankester A. C., Cleton-Jansen A. M., Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clinical Cancer Research 2011 17 8 2110 2119 2-s2.0-79954573473 10.1158/1078-0432.CCR-10-2047
133. Whelan J., Patterson D., Perisoglou M., Bielack S., Marina N., Smeland S., Bernstein M., The role of interferons in the treatment of osteosarcoma. Pediatric Blood and Cancer 2010 54 3 350 354 2-s2.0-76749141740 10.1002/pbc.22136
134. Li Z., Xu Q., Peng H., Cheng R., Sun Z., Ye Z., IFN- γ enhances HOS and U2OS cell lines susceptibility to γ δ T cell-mediated killing through the Fas/Fas ligand pathway. International Immunopharmacology 2011 11 4 496 503 2-s2.0-79952737137 10.1016/j.intimp.2011.01.001
135. Kager L., Potschger U., Bielack S., Review of mifamurtide in the treatment of patients with osteosarcoma. Therapeutics and Clinical Risk Management 2010 6 279 286
136. Wittrant Y., Théoleyre S., Chipoy C., Padrines M., Blanchard F., Heymann D., Rédini F., RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochimica et Biophysica Acta 2004 1704 2 49 57 2-s2.0-4444257291 10.1016/j.bbcan.2004.05.002
137. Jones D. H., Nakashima T., Sanchez O. H., Kozieradzki I., Komarova S. V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C. V., Komnenovic V., Kong Y. Y., Schreiber M., Dixon S. J., Sims S. M., Khokha R., Wada T., Penninger J. M., Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006 440 7084 692 696 2-s2.0-33645453481 10.1038/nature04524
138. Avnet S., Longhi A., Salerno M., Halleen J. M., Perut F., Granchi D., Ferrari S., Bertoni F., Giunti A., Baldini N., Increased osteoclast activity is associated with aggressiveness of osteosarcoma. International Journal of Oncology 2008 33 6 1231 1238 2-s2.0-59049105619 10.3892/ijo-00000113
139. Lee J. A., Jung J. S., Kim D. H., Lim J. S., Kim M. S., Kong C. B., Song W. S., Cho W. H., Jeon D. G., Lee S. Y., Koh J. S., RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatric Blood and Cancer 2011 56 5 738 743 2-s2.0-79952131163 10.1002/pbc.22720
140. Zhou Z., Guan H., Duan X., Kleinerman E. S., Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005 104 8 1713 1720 2-s2.0-26444574115 10.1002/cncr.21383
141. Tenta R., Pitulis N., Tiblalexi D., Consoulas C., Katopodis H., Konstantinidou E., Manoussakis M., Kletsas D., Alexis M. N., Poyatzi A., Koutsilieris M., Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells. Hormone and Metabolic Research 2008 40 11 737 745 2-s2.0-57149117639 10.1055/s-2008-1078753
142. Iguchi T., Miyakawa Y., Saito K., Nakabayashi C., Nakanishi M., Saya H., Ikeda Y., Kizaki M., Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. International Journal of Oncology 2007 31 2 285 291 2-s2.0-35148836243
143. Ory B., Blanchard F., Battaglia S., Gouin F., Rédini F., Heymann D., Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Molecular Pharmacology 2007 71 1 333 343 2-s2.0-33845910925 10.1124/mol.106. 028837
144. Evdokiou A., Labrinidis A., Bouralexis S., Hay S., Findlay D. M., Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003 33 2 216 228 2-s2.0-0141455522 10.1016/S8756- 3282(03)00223-0
145. Fu D., He X., Yang S., Xu W., Lin T., Feng X., Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro. BMC Musculoskeletal Disorders 2011 12, article 146 2-s2.0-79959683418 10.1186/1471-2474-12-146
146. Heymann D., Ory B., Blanchard F., Heymann M. F., Coipeau P., Charrier C., Couillaud S., Thiery J. P., Gouin F., Redini F., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005 37 1 74 86 2-s2.0-20544442197 10.1016/j.bone.2005.02.020
147. Labrinidis A., Hay S., Liapis V., Findlay D. M., Evdokiou A., Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. International Journal of Cancer 2010 127 2 345 354 2-s2.0-77953690136 10.1002/ijc.25051
148. Dass C. R., Choong P. F. M., Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Molecular Cancer Therapeutics 2007 6 12 3263 3270 2-s2.0-37549048038 10.1158/1535-7163.MCT-07-0546
149. Koto K., Horie N., Kimura S., Murata H., Sakabe T., Matsui T., Watanabe M., Adachi S., Maekawa T., Fushiki S., Kubo T., Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Letters 2009 274 2 271 278 2-s2.0-58149296145 10.1016/j.canlet. 2008.09.026
150. Endo-Munoz L., Cumming A., Rickwood D., Wilson D., Cueva C., Ng C., Strutton G., Cassady A. I., Evdokiou A., Sommerville S., Dickinson I., Guminski A., Saunders N. A., Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Research 2010 70 18 7063 7072 2-s2.0-77956913447 10.1158/0008-5472.CAN-09-4291
151. Benassi M. S., Chiechi A., Ponticelli F., Pazzaglia L., Gamberi G., Zanella L., Manara M. C., Perego P., Ferrari S., Picci P., Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Letters 2007 250 2 194 205 2-s2.0-34047129164 10.1016/j.canlet.2006.10.004
152. Ryu K., Murata H., Koto K., Horie N., Matsui T., Nishigaki Y., Sakabe T., Takeshita H., Itoi M., Kimura S., Ashihara E., Maekawa T., Fushiki S., Kubo T., Combined effects of bisphosphonate and radiation on osteosarcoma cells. AntiCancer Research 2010 30 7 2713 2720 2-s2.0-77955807398
153. Odri G. A., Dumoucel S., Picarda G., Battaglia S., Lamoureux F., Corradini N., Rousseau J., Tirode F., Laud K., Delattre O., Gouin F., Heymann D., Redini F., Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Research 2010 70 19 7610 7619 2-s2.0-77957337429 10.1158/0008-5472.CAN-09-4272
154. Battaglia S., Dumoucel S., Chesneau J., Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. Journal of Bone and Mineral Research 2011 26 10 2439 2451
155. Akiyama T., Dass C. R., Shinoda Y., Kawano H., Tanaka S., Choong P. F. M., Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. Journal of Pharmacy and Pharmacology 2010 62 4 470 476 2-s2.0-77952798405 10.1211/jpp/62.04.0009
156. Lamoureux F., Picarda G., Rousseau J., Gourden C., Battaglia S., Charrier C., Pitard B., Heymann D., Rédini F., Therapeutic efficacy of soluble receptor activator of nuclear factor- B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Molecular Cancer Therapeutics 2008 7 10 3389 3398 2-s2.0-55749083203 10.1158/1535-7163.MCT-08-0497
157. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., Blanchard F., Gouin F., Pitard B., Heymann D., Redini F., Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Research 2007 67 15 7308 7318 2-s2.0-34547629223 10.1158/0008-5472.CAN-06-4130
158. Rousseau J., Escriou V., Lamoureux F., Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. Journal of Bone and Mineral Research 2011 26 10 2452 2462
159. Guan H., Zhou Z., Cao Y., Duan X., Kleinerman E. S., VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL. Oncology Research 2009 18 2-3 117 125 2-s2.0-75649112276 10.3727/ 096504009789954627
160. Taylor R., Knowles H. J., Athanasou N. A., Ewing sarcoma cells express RANKL and support osteoclastogenesis. Journal of Pathology 2011 225 2 195 202 2-s2.0-79955554386 10.1002/path.2869
161. Fizazi K., Lipton A., Mariette X., Body J. J., Rahim Y., Gralow J. R., Gao G., Wu L., Sohn W., Jun S., Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology 2009 27 10 1564 1571 2-s2.0-63749094012 10.1200/JCO.2008.19.2146
162. Thomas D., Chawla S. P., Skubitz K., Denosumab treatment of giant cell tumor of bone: interim analysis of an open-label phase II study. Journal of Clinical Oncology 2008 26, supplement, abstract 10500
163. Henriksen G., Breistøl K., Bruland Ø. S., Fodstad Ø., Larsen R. H., Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Research 2002 62 11 3120 3125 2-s2.0-0036606104
164. Anderson P., Nuñez R., Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Review of Anticancer Therapy 2007 7 11 1517 1527 2-s2.0-37349120734 10.1586/14737140.7.11. 1517
165. Loeb D. M., Hobbs R. F., Okoli A., Chen A. R., Cho S., Srinivasan S., Sgouros G., Shokek O., Wharam M. D., Scott T., Schwartz C. L., Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer 2010 116 23 5470 5478 2-s2.0-78649594834 10.1002/cncr.25518
166. Parker C., Nilsson S., Heinrich D., Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). Journal of Clinical Oncology 2012 30, supplement, abstract LBA4512
167. Hirotsu M., Setoguchi T., Sasaki H., Matsunoshita Y., Gao H., Nagao H., Kunigou O., Komiya S., Smoothened as a new therapeutic target for human osteosarcoma. Molecular Cancer 2010 9, article 5 2-s2.0-76849102604 10.1186/1476-4598-9-5
168. Beauchamp E. M., Ringer L., Bulut G., Sajwan K. P., Hall M. D., Lee Y. C., Peaceman D., Özdemirli M., Rodriguez O., Macdonald T. J., Albanese C., Toretsky J. A., Üren A., Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. Journal of Clinical Investigation 2011 121 1 148 160 2-s2.0-78650958235 10.1172/JCI42874
169. Warzecha J., Göttig S., Chow K. U., Brüning C., Percic D., Boehrer S., Brude E., Kurth A., Inhibition of osteosarcoma cell proliferation by the hedgehog-inhibitor cyclopamine. Journal of Chemotherapy 2007 19 5 554 561 2-s2.0-36549057017
170. Zhao H., Guo W., Peng C., Ji T., Lu X., Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis. Molecular Biology Reports 2010 37 5 2509 2515 2-s2.0-77955657776 10.1007/s11033-009-9765-2
171. Kim J., Tang J. Y., Gong R., Kim J., Lee J. J., Clemons K. V., Chong C. R., Chang K. S., Fereshteh M., Gardner D., Reya T., Liu J. O., Epstein E. H., Stevens D. A., Beachy P. A., Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 2010 17 4 388 399 2-s2.0-77950492233 10.1016/j.ccr.2010.02.027
172. Fouladi M., Park J. R., Stewart C. F., Gilbertson R. J., Schaiquevich P., Sun J., Reid J. M., Ames M. M., Speights R., Ingle A. M., Zwiebel J., Blaney S. M., Adamson P. C., Pediatric phase I trial and pharmacokinetic study of vorinostat: a children's oncology group phase I consortium report. Journal of Clinical Oncology 2010 28 22 3623 3629 2-s2.0-77955900071 10.1200/JCO.2009.25. 9119
173. Su J. M., Li X. N., Thompson P., Ou C. N., Ingle A. M., Russell H., Lau C. C., Adamson P. C., Blaney S. M., Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clinical Cancer Research 2011 17 3 589 597 2-s2.0-79551691082 10.1158/1078-0432.CCR-10-0738
174. Hirose T., Sowa Y., Takahashi S., Saito S., Yasuda C., Shindo N., Furuichi K., Sakai T., p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 2003 22 49 7762 7773 2-s2.0-0344873745 10.1038/sj.onc.1207091
175. Blattmann C., Oertel S., Ehemann V., Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. International Journal of Radiation Oncology, Biology, Physics 2010 78 1 237 245
176. Wittenburg L. A., Bisson L., Rose B. J., Korch C., Thamm D. H., The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemotherapy and Pharmacology 2011 67 1 83 92 2-s2.0-77956311554 10.1007/s00280-010-1287-z
177. Yang C., Choy E., Hornicek F. J., Wood K. B., Schwab J. H., Liu X., Mankin H., Duan Z., Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemotherapy and Pharmacology 2011 67 2 439 446 2-s2.0-77956335478 10.1007/s00280-010-1344-7
178. Koshkina N. V., Rao-Bindal K., Kleinerman E. S., Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 2011 117 15 3457 3467 2-s2.0-79960698626 10.1002/cncr.25884
179. Watanabe K., Okamoto K., Yonehara S., Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death and Differentiation 2005 12 1 10 18 2-s2.0-11844298984 10.1038/sj.cdd.4401507
180. Yamanegi K., Yamane J., Kobayashi K., Kato-Kogoe N., Ohyama H., Nakasho K., Yamada N., Hata M., Nishioka T., Fukunaga S., Futani H., Okamura H., Terada N., Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncology Reports 2010 24 6 1621 1627 2-s2.0-78649396020 10.3892/or-00001026
181. Sakimura R., Tanaka K., Nakatani F., Matsunobu T., Li X., Hanada M., Okada T., Nakamura T., Matsumoto Y., Iwamoto Y., Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. International Journal of Cancer 2005 116 5 784 792 2-s2.0-23244432614 10.1002/ijc.21069
182. Nakatani F., Tanaka K., Sakimura R., Matsumoto Y., Matsunobu T., Li X., Hanada M., Okada T., Iwamoto Y., Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. Journal of Biological Chemistry 2003 278 17 15105 15115 2-s2.0-0038689323 10.1074/jbc.M211470200
183. Sonnemann J., Dreyer L., Hartwig M., Palani C. D., Hong L. T. T., Klier U., Bröker B., Völker U., Beck J. F., Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. Journal of Cancer Research and Clinical Oncology 2007 133 11 847 858 2-s2.0-36849016900 10.1007/s00432-007-0227-8
184. Okada T., Tanaka K., Nakatani F., Sakimura R., Matsunobu T., Li X., Hanada M., Nakamura T., Oda Y., Tsuneyoshi M., Iwamoto Y., Involvement of P-glycoprotein and MMP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. International Journal of Cancer 2006 118 1 90 97 2-s2.0-27944434891 10.1002/ijc.21297
185. Matsubara H., Watanabe M., Imai T., Yui Y., Mizushima Y., Hiraumi Y., Kamitsuji Y., Watanabe K. I., Nishijo K., Toguchida J., Nakahata T., Adachi S., Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S, 4S, 7Z, 10S, 16E, 21R)-7- ethylidene-4, 21-bis(propan-2-yl)-2-oxa-12, 13-dithia-5, 8, 20, 23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone] . Journal of Pharmacology and Experimental Therapeutics 2009 328 3 839 848 2-s2.0-62449097362 10.1124/jpet.108.147462
186. Martins A. S., Ordoñez J. L., García-Sánchez A., Herrero D., Sevillano V., Osuna D., Mackintosh C., Caballero G., Otero A. P., Poremba C., Madoz-Gúrpide J., De Alava E., A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Research 2008 68 15 6260 6270 2-s2.0-51049098720 10.1158/0008-5472.CAN-07-3074
187. Bagatell R., Beliakoff J., David C. L., Marron M. T., Whitesell L., Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. International Journal of Cancer 2005 113 2 179 188 2-s2.0-10344225631 10.1002/ijc.20611
188. Gaspar N., Sharp S. Y., Pacey S., Jones C., Walton M., Vassal G., Eccles S., Pearson A., Workman P., Acquired resistance to 17-Allylamino-17- Demethoxygeldanamycin (17-A AG, Tanespimycin) in glioblastoma cells. Cancer Research 2009 69 5 1966 1975 2-s2.0-62449226171 10.1158/0008-5472.CAN-08-3131